17.21
0.06 (0.35%)
| Penutupan Terdahulu | 17.15 |
| Buka | 17.08 |
| Jumlah Dagangan | 128,919 |
| Purata Dagangan (3B) | 242,000 |
| Modal Pasaran | 461,529,760 |
| Harga / Pendapatan (P/E Ke hadapan) | 16.05 |
| Harga / Jualan (P/S) | 7.19 |
| Harga / Buku (P/B) | 21.95 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Mar 2026 |
| Margin Keuntungan | -9.48% |
| Margin Operasi (TTM) | -2.72% |
| EPS Cair (TTM) | -0.180 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 116.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 123.34% |
| Nisbah Semasa (MRQ) | 1.97 |
| Aliran Tunai Operasi (OCF TTM) | 5.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -14.13 M |
| Pulangan Atas Aset (ROA TTM) | -2.02% |
| Pulangan Atas Ekuiti (ROE TTM) | -22.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Eton Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 3.00 |
|
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.39% |
| % Dimiliki oleh Institusi | 53.50% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 37.00 (HC Wainwright & Co., 114.99%) | Beli |
| Median | 33.50 (94.65%) | |
| Rendah | 30.00 (Craig-Hallum, 74.32%) | Beli |
| Purata | 33.50 (94.65%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 17.80 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Craig-Hallum | 03 Mar 2026 | 30.00 (74.32%) | Beli | 17.45 |
| HC Wainwright & Co. | 02 Mar 2026 | 37.00 (114.99%) | Beli | 18.15 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |